| Disease Specific Interactions between Host Protein and DME (HOSPPI) |
| ICD Disease Classification Healthy |
| ICD-11: Healthy |
Click to Show/Hide the Full List of HOSPPI: 3 HOSPPI
|
| Oligomerization |
| Cytochrome b5 (CYB5A) |
Health |
Heterooligomer |
| Uniprot ID |
|
| Interaction Name |
CYB5A-CYP2C8 heterooligomerization |
[1] |
| Studied Cell Lines |
DLPC vesicles |
| Description |
Cytochrome b5 (CYB5A) is reported to heterooligomerize with the CYP2C8 protein, which leads to an increased activity of the drug-metabolizing enzyme Cytochrome P450 2C8. As a result, the interaction between CYB5A and CYP2C8 can facilitate the drug-metabolizing process of Cytochrome P450 2C8. |
| Non-coding RNA regulation |
| hsa-miR-103a-3p |
Health |
Suppression |
| miRBase ID |
|
| Interaction Name |
hsa-miR-103a-3p--CYP2C8 regulation |
[2] |
| Studied Cell Lines |
Hepatocytes |
| Description |
hsa-miR-103a-3p is reported to suppress CYP2C8 mRNA translation by binding to the 3' untranslated region (3'UTR) of CYP2C8 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Cytochrome P450 2C8. |
| hsa-miR-107 |
Health |
Suppression |
| miRBase ID |
|
| Interaction Name |
hsa-miR-107--CYP2C8 regulation |
[2] |
| Studied Cell Lines |
Hepatocytes |
| Description |
hsa-miR-107 is reported to suppress CYP2C8 mRNA translation by binding to the 3' untranslated region (3'UTR) of CYP2C8 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Cytochrome P450 2C8. |
| ICD Disease Classification 02 Neoplasms |
| ICD-11: 2C12 Liver cancer |
Click to Show/Hide the Full List of HOSPPI: 2 HOSPPI
|
| Oligomerization |
| Progesterone receptor 1 (PGRMC1) |
Liver cancer |
Heterooligomer |
| Uniprot ID |
|
| Interaction Name |
PGRMC1-CYP2C8 heterooligomerization |
[4] |
| Studied Cell Lines |
Human embryonic kidney cell line (HEK293) and Human liver cancer cell line (HepG2) |
| Affected Substrate(s): |
Luciferin (Metabolic product: Luciferin 6' methyl ether O-demethylation)
|
| Description |
Progesterone receptor 1 (PGRMC1) is reported to heterooligomerize with the CYP2C8 protein, which leads to a suppressed activity of the drug-metabolizing enzyme Cytochrome P450 2C8. As a result, the interaction between PGRMC1 and CYP2C8 can inhibit the drug-metabolizing process of Cytochrome P450 2C8. |
| Transcription-factor regulation |
| Hepatocyte NF 4-alpha (HNF4A) |
Liver cancer |
Activation |
| Uniprot ID |
|
| Interaction Name |
HNF4A-CYP2C8 interaction |
[3] |
| Studied Cell Lines |
HepG2 cell line |
| Ensembl ID |
|
| Description |
Hepatocyte NF 4-alpha (HNF4A) is reported to activate the transcription of CYP2C8 gene, which leads to an increased expression of the drug-metabolizing enzyme Cytochrome P450 2C8. As a result, the interaction between HNF4A and CYP2C8 can activate the drug-metabolizing process of Cytochrome P450 2C8. |
|
|
|
|
|
|
